Abstract
Purpose
To investigate the risk of bladder cancer (BCa) in patients treated with brachytherapy for prostate cancer (PCa).
Methods
We retrospectively analyzed 583 patients with PCa who underwent brachytherapy with or without external beam radiotherapy (EBRT). We analyzed the disease-free survival (DFS) of BCa in patients with PCa who underwent brachytherapy with or without EBRT. We performed multivariate Cox regression analyses of DFS using age, EBRT, and Brinkman index (BI) score (number of cigarettes smoked per day × number of years smoking) ≥ 200 as variables for BCa after brachytherapy.
Results
Fourteen patients (2.4%) developed BCa after brachytherapy with or without EBRT. The percentage of high-grade urothelial carcinoma (UC) was 63.6%. A total of 85.7% of patients had non-muscle invasive BCa, and 14.3% of patients had muscle invasive BCa. DFS was longer in brachytherapy monotherapy than in combination therapy (brachytherapy + EBRT). Multivariate Cox regression analysis showed that a BI score ≥ 200 (Hazard Ratio (HR 8.61; 95% Confidence Interval (CI) 1.12–65.98) and EBRT combination (HR 3.29; 95% CI 1.03–10.52) were significantly associated with BCa development in patients with PCa treated with brachytherapy. Furthermore, patients with BI score ≥ 200 and EBRT combination had a significantly higher risk of BCa compared with patients with BI score < 200 (HR Log-rank test P = 0.010).
Conclusion
Most cases of BCa after brachytherapy with or without EBRT are high grade and invasive. We hypothesized that the EBRT combination might be a risk factor for BCa in patients with PCa who underwent brachytherapy.
Similar content being viewed by others
Data availability
The datasets analyzed during the current study are available from the corresponding author upon reasonable request.
References
Cooperberg MR, Broering JM, Litwin MS et al (2004) The contemporary management of prostate cancer in the United States: lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CapSURE), a national disease registry. J Urol 171(4):1393–1401
Best T, Li D, Skol AD et al (2011) Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin’s lymphoma. Nat Med 17(8):941–943
Boorjian S, Cowan JE, Konety BR et al (2007) Bladder cancer incidence and risk factors in men with prostate cancer: results from cancer of the prostate strategic urologic research endeavor. J Urol 177(3):883–887 (Discussion 887)
Liauw SL, Sylvester JE, Morris CG, Blasko JC, Grimm PD (2006) Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. Int J Radiat Oncol Biol Phys 66(3):669–673
Yoshida T, Kates M, Fujita K, Bivalacqua TJ, McConkey DJ (2019) Predictive biomarkers for drug response in bladder cancer. Int J Urol 26(11):1044–1053
Sandhu JS, Vickers AJ, Bochner B, MacheleDonat S, Herr HW, Dalbagni G (2006) Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer. BJU Int 98(1):59–62
Yee DS, Shariat SF, Lowrance WT et al (2010) Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer. J Urol 183(5):1751–1756
Funding
None.
Author information
Authors and Affiliations
Contributions
TM: project development, data collection, data analysis, manuscript writing. KF: data analysis, manuscript writing. MH: data collection. MN: data collection. SA: data collection. EB: data analysis. MN: project development, data collection. KN: data collection. KY: project development, data collection. MI: data collection. MY: data collection. KN: project development, data collection. HU: project development, data collection.
Corresponding author
Ethics declarations
Conflict of interest
All authors declare no conflicts of interest.
Research involving human participants and/or animals
The study protocol was approved by the Institutional Ethics Review Board of Kindai University (approval no. R02-155).
Informed consent
Written informed consent was waived owing to the retrospective design.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Minami, T., Fujita, K., Hashimoto, M. et al. External beam radiotherapy combination is a risk factor for bladder cancer in patients with prostate cancer treated with brachytherapy. World J Urol 41, 1317–1321 (2023). https://doi.org/10.1007/s00345-023-04380-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-023-04380-5